CoChat
Sign Up
Cited by 330Liver Disease Diagnosis and TreatmentDiet, Metabolism, and DiseaseAlcohol Consumption and Health Effects

The DOI matches its Crossref record; 239 of the 244 references it cites were found in a registry or an index.

Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans

Open access
Pafili, Kalliopi, Roden, Michael·2021·Molecular Metabolism
DOI 10.1016/j.molmet.2020.101122PMC PMC8324683
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) comprises hepatic alterations with increased lipid accumulation (steatosis) without or with inflammation (nonalcoholic steatohepatitis, NASH) and/or fibrosis in the absence of other causes of liver disease. NAFLD is developing as a burgeoning health challenge, mainly due to the worldwide obesity and diabetes epidemics. SCOPE OF REVIEW: This review summarizes the knowledge on the pathogenesis underlying NAFLD by focusing on studies in humans and on hypercaloric nutrition, including effects of saturated fat and fructose, as well as adipose tissue dysfunction, leading to hepatic lipotoxicity, abnormal mitochondrial function, and oxidative stress, and highlights intestinal dysbiosis. These mechanisms are discussed in the context of current treatments targeting metabolic pathways and the results of related clinical trials. MAJOR CONCLUSIONS: Recent studies have provided evidence that certain conditions, for example, the severe insulin-resistant diabetes (SIRD) subgroup (cluster) and the presence of an increasing number of gene variants, seem to predispose for excessive risk of NAFLD and its accelerated progression. Recent clinical trials have been frequently unsuccessful in halting or preventing NAFLD progression, perhaps partly due to including unselected cohorts in later stages of NAFLD. On the basis of this literature review, this study proposed screening in individuals with the highest genetic or acquired risk of disease progression, for example, the SIRD subgroup, and developing treatment concepts targeting the earliest pathophysiolgical alterations, namely, adipocyte dysfunction and insulin resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.molmet.2020.101122

Cites

239 of 240 references verified1 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Pathogenetic mechanisms driving the progression of human NAFLD and key pathways of therapeutic interventions. High caloric intake induces changes in the gut microbiota and enlargement of the adipose tissue. Diet and bariatric surgery are the main treatment strategies in this context. Gut dysbiosis is associated with disruption of intercellular tight junctions [87], which permit the translocation of bacterial lipopolysaccharide (LPS) into the systemic circulation and increase alcohol-producing bacteria [85]. The patatin-like phospholipase domain-containing protein 3 (PNPLA3) genetic variant increases adipose tissue lipolysis [17], increasing the flux of substrates and signaling molecules to the liver [92]. Adipose tissue–liver cross talk is further mediated through the secretion of exosomes [97] and adipokines [94]. Steatotic hepatocytes are characterized by a potentially upregulated uptake of FFA. Additionally, enhanced DNL converts acetyl-CoA to new fatty acids [109,112]. The genetic variant of the gene glucokinase regulatory protein (GCKR) contributes to elevated DNL, through increase in substrates availability [43]. In this context, mitochondrial fatty acid oxidation is upregulated [121]. Export of triglycerides as VLDL particles is compromised through reduced lipidation of microsomal triglyceride transfer protein (MTTP), the enzyme that catalyzes the lipidation of apolipoprotein B100 (apoB100) [138]. The transmembrane 6 superfamily member 2 (TM6SF2) genetic variant further attenuates the ability of hepatocytes to mobilize neutral lipids for the VLDL assembly [38]. Mitochondrial pyruvate carrier inhibitors (MPCi) decrease carbon flow into the tricarboxylic acid (TCA) cycle and therefore alter the ability of hepatic mitochondria to fuel DNL. A number of further pharmacological agents including fibroblast growth factor agonists (FGF21a), peroxisome proliferator-activated receptor (PPAR) ɑ agonists (PPARαa), thyroid hormone receptor-β agonists (THR-βa), and farnesoid X receptor agonists (FXRa) mainly aim to augment fatty acid oxidation, and DNL is targeted by ketohexokinase inhibitors (KHKi), stearoyl-CoA desaturase 1 inhibitors (SCD-1i), mitochondrial pyruvate carrier inhibitors (MPCi), and FXRa and acetyl coenzyme A carboxylase inhibitors (ACC1/2i). Following progression to NASH, production of sn-1,2-DAG and sphingolipids is favored. In NASH, the sn-1,2-DAG–PKCε pathway tightly correlates with hepatic insulin resistance [115]; hepatic dihydroceramides correlate with hepatic oxidative stress and inflammation [118]. Following progression to NASH, mitochondrial flexibility is lost, leading to decreased fatty acid oxidation [121] and oxidative stress and then inflammation [118], leading to hepatocytes apoptosis. Resident macrophage cells in the liver, the Kupffer cells, are increased and release proinflammatory cytokines [143]. Finally, HSC activation is regarded as a key initiating event in hepatic fibrogenesis, with activated HSC being characterized by enhanced extracellular matrix (ECM) production. Among other factors, the transforming growth factor β (TGF- β) initiates ECM gene expression in quiescent HSC [148]. Chemokine receptor (CCR2/5) antagonists and pan-PPARa mainly exert antifibrotic properties. ACC 1/2i, acetyl coenzyme A carboxylase 1/2 inhibitors; a: agonists, apoB100, apolipoprotein B100; βox, β oxidation; CER, ceramides; ChREBP, carbohydrate regulatory element binding protein; CCR, chemokine receptor; CD36, Cluster of differentiation 36; CPT1, carnitine palmitoyltransferase 1; DAG, diacylglycerols; DNL, de novo lipogenesis; ER, endoplasmic reticulum; ECM, extracellular matrix; Fa-CoA, fatty acyl-CoA; FATP, fatty acid transporters; FGF, fibroblast growth factor; FFA, free fatty acids; fruc, fructose; FXR, farnesoid X receptor; GCKR, glucokinase regulatory protein; GLP-1 RA, glucagon-like peptide 1 receptor agonists (GLP-1 RA); HC, hepatocyte; HSCs, hepatic stellate cells; i, inhibitors; IL-1β, interleukin 1β; IL-6, interleukin 6; IL-6R, interleukin 6 receptro; IR, insulin receptor; JNK, c-Jun N-terminal kinase; KHKi, ketohexokinase inhibitors; LD, lipid droplet; LPS, lipopolysaccharide; MPCi, mitochondrial pyruvate carrier inhibitors; MTTP, microsomal triglyceride transfer protein; NF-κB: nuclear factor κ-light-chain-enhancer of activated B cells; PNPLA3, patatin-like phospholipase domain-containing protein 3; PPAR, peroxisome proliferator-activated receptor; pyr, pyruvate, SCD-1i, stearoyl-CoA desaturase 1 inhibitors; SGLT-2i, sodium glucose cotransporter-2 inhibitors; SREBP1c, sterol regulatory element binding protein 1c; TAG, triacylglycerol; TCA, tricarboxylic acid; TGF-β, transforming growth factor-β; THR, thyroid hormone receptor; TLR-4, toll-like receptor-4; TNF-α, tumor necrosis factor-α; TNFR, tumor necrosis factor receptor; TM6SF2, transmembrane 6 superfamily member 2; VLDL, very low density lipoprotein.
Figure 1 Pathogenetic mechanisms driving the progression of human NAFLD and key pathways of therapeutic interventions. High caloric intake induces changes in the gut microbiota and enlargement of the adipose tissue. Diet and bariatric surgery are the main treatment strategies in this context. Gut dysbiosis is associated with disruption of intercellular tight junctions [87], which permit the translocation of bacterial lipopolysaccharide (LPS) into the systemic circulation and increase alcohol-producing bacteria [85]. The patatin-like phospholipase domain-containing protein 3 (PNPLA3) genetic variant increases adipose tissue lipolysis [17], increasing the flux of substrates and signaling molecules to the liver [92]. Adipose tissue–liver cross talk is further mediated through the secretion of exosomes [97] and adipokines [94]. Steatotic hepatocytes are characterized by a potentially upregulated uptake of FFA. Additionally, enhanced DNL converts acetyl-CoA to new fatty acids [109,112]. The genetic variant of the gene glucokinase regulatory protein (GCKR) contributes to elevated DNL, through increase in substrates availability [43]. In this context, mitochondrial fatty acid oxidation is upregulated [121]. Export of triglycerides as VLDL particles is compromised through reduced lipidation of microsomal triglyceride transfer protein (MTTP), the enzyme that catalyzes the lipidation of apolipoprotein B100 (apoB100) [138]. The transmembrane 6 superfamily member 2 (TM6SF2) genetic variant further attenuates the ability of hepatocytes to mobilize neutral lipids for the VLDL assembly [38]. Mitochondrial pyruvate carrier inhibitors (MPCi) decrease carbon flow into the tricarboxylic acid (TCA) cycle and therefore alter the ability of hepatic mitochondria to fuel DNL. A number of further pharmacological agents including fibroblast growth factor agonists (FGF21a), peroxisome proliferator-activated receptor (PPAR) ɑ agonists (PPARαa), thyroid hormone receptor-β agonists (THR-βa), and farnesoid X receptor agonists (FXRa) mainly aim to augment fatty acid oxidation, and DNL is targeted by ketohexokinase inhibitors (KHKi), stearoyl-CoA desaturase 1 inhibitors (SCD-1i), mitochondrial pyruvate carrier inhibitors (MPCi), and FXRa and acetyl coenzyme A carboxylase inhibitors (ACC1/2i). Following progression to NASH, production of sn-1,2-DAG and sphingolipids is favored. In NASH, the sn-1,2-DAG–PKCε pathway tightly correlates with hepatic insulin resistance [115]; hepatic dihydroceramides correlate with hepatic oxidative stress and inflammation [118]. Following progression to NASH, mitochondrial flexibility is lost, leading to decreased fatty acid oxidation [121] and oxidative stress and then inflammation [118], leading to hepatocytes apoptosis. Resident macrophage cells in the liver, the Kupffer cells, are increased and release proinflammatory cytokines [143]. Finally, HSC activation is regarded as a key initiating event in hepatic fibrogenesis, with activated HSC being characterized by enhanced extracellular matrix (ECM) production. Among other factors, the transforming growth factor β (TGF- β) initiates ECM gene expression in quiescent HSC [148]. Chemokine receptor (CCR2/5) antagonists and pan-PPARa mainly exert antifibrotic properties. ACC 1/2i, acetyl coenzyme A carboxylase 1/2 inhibitors; a: agonists, apoB100, apolipoprotein B100; βox, β oxidation; CER, ceramides; ChREBP, carbohydrate regulatory element binding protein; CCR, chemokine receptor; CD36, Cluster of differentiation 36; CPT1, carnitine palmitoyltransferase 1; DAG, diacylglycerols; DNL, de novo lipogenesis; ER, endoplasmic reticulum; ECM, extracellular matrix; Fa-CoA, fatty acyl-CoA; FATP, fatty acid transporters; FGF, fibroblast growth factor; FFA, free fatty acids; fruc, fructose; FXR, farnesoid X receptor; GCKR, glucokinase regulatory protein; GLP-1 RA, glucagon-like peptide 1 receptor agonists (GLP-1 RA); HC, hepatocyte; HSCs, hepatic stellate cells; i, inhibitors; IL-1β, interleukin 1β; IL-6, interleukin 6; IL-6R, interleukin 6 receptro; IR, insulin receptor; JNK, c-Jun N-terminal kinase; KHKi, ketohexokinase inhibitors; LD, lipid droplet; LPS, lipopolysaccharide; MPCi, mitochondrial pyruvate carrier inhibitors; MTTP, microsomal triglyceride transfer protein; NF-κB: nuclear factor κ-light-chain-enhancer of activated B cells; PNPLA3, patatin-like phospholipase domain-containing protein 3; PPAR, peroxisome proliferator-activated receptor; pyr, pyruvate, SCD-1i, stearoyl-CoA desaturase 1 inhibitors; SGLT-2i, sodium glucose cotransporter-2 inhibitors; SREBP1c, sterol regulatory element binding protein 1c; TAG, triacylglycerol; TCA, tricarboxylic acid; TGF-β, transforming growth factor-β; THR, thyroid hormone receptor; TLR-4, toll-like receptor-4; TNF-α, tumor necrosis factor-α; TNFR, tumor necrosis factor receptor; TM6SF2, transmembrane 6 superfamily member 2; VLDL, very low density lipoprotein.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Ratziu, 2018, One-year results of the global phase 2b randomized placebo-controlled arrest trial of aramchol, a stearoyl CoA desaturase inhibitor, in patients with NASH, Hepatology, 68

Cited by

Sorted by citations

See all 330

Related

See all

Metadata

Authors
Pafili, K., & Roden, M.
Affiliations
Deutsches Diabetes-Zentrum e.V. (DE)
Corresponding author
Roden, Michael
ORCID
Venue
Molecular Metabolism
Publisher
Elsevier BV
Published
2021-08
Volume
50
Pages
101122
ISSN
2212-8778 (ISSN-L)
DOI
10.1016/j.molmet.2020.101122
PMC
PMC8324683
OpenAlex
W3104053913
Cited by
330
References
244
Citations by year
2026: 47 · 2025: 63 · 2024: 85 · 2023: 73 · 2022: 40 · 2021: 19
FWCI
4.89
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Metabolism (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Ministry of Innovation, Science, Research and Technology of the State of North Rhine-Westphalia
  • Deutsche Forschungsgemeinschaft (CRC 1116/2)
  • Bundesministerium für Bildung und Forschung
  • Bundesministerium für Gesundheit
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords
non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, hepatic steatosis, liver fibrosis, saturated fat, fructose, adipose tissue dysfunction, hepatic lipotoxicity, mitochondrial dysfunction, oxidative stress, gut dysbiosis, severe insulin-resistant diabetes, genetic risk variants, NAFLD progression, NAFLD screening, insulin resistance, NAFLD treatment
MeSH terms
Diabetes Mellitus, Type 2, Fatty Acids, Humans, Insulin Resistance, Liver, Mitochondria, Obesity, Genetic Variation, Adipocytes, Oxidative Stress, Disease Progression, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Lipid Metabolism, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review